CFDE Data Portal | Search ISLR2-AS1

	Label	Description
	ISLR2-AS1 Gene (Entity type)	ENSG00000248540 - ISLR2 antisense RNA 1
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 10 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE115542 digoxin 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE210682 0 V 3 METHADONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE133447 GSE133448 MED25 ETV4 knockdown UFERSA-PC3 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE149632 dopamine 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS

ISLR2-AS1

ENSG00000248540 - ISLR2 antisense RNA 1

GSE216273 GSE216292 palbociclib 14 v 1 human dn

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE100148 EZH2 inhibition 10 v 5 human dn

A Gene Set from LINCS

GSE115542 digoxin 2 v 0 human up

A Gene Set from LINCS

GSE210682 0 V 3 METHADONE HUMAN DN

A Gene Set from LINCS

GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE DN

A Gene Set from LINCS

GSE133447 GSE133448 MED25 ETV4 knockdown UFERSA-PC3 2 v 0 human up

A Gene Set from LINCS

GSE149632 dopamine 0 v 6 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.